ConductScience.org, home

Paper28039262

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

Dong ZY and 18 others. Clin Cancer Res, 2017. Cited by 852 papers, by iCite.

Cite this record

ConductScience Library. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Papers, record 28039262. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28039262

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
PubMed
Journal
Clin Cancer Res
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
852
iCite
Relative citation ratio, by iCite
24.5
iCite
Revised in PubMed
2022-04-10
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dong ZYZhong-Yi
2Zhong WZWen-Zhao
3Zhang XCXu-Chao
4Su JJian
5Xie ZZhi
6Liu SYSi-Yang
7Tu HYHai-Yan
8Chen HJHua-Jun
9Sun YLYue-Li
10Zhou QQing
11Yang JJJin-Ji
12Yang XNXue-Ning
13Lin JXJia-Xin
14Yan HHHong-Hong
15Zhai HRHao-Ran
16Yan LXLi-Xu
17Liao RQRi-Qiang
18Wu SPSi-Pei
19Wu YLYi-Long

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AdenocarcinomaMajor topic
B7-H1 AntigenMajor topic
ImmunotherapyMajor topic
Lung NeoplasmsMajor topic
Programmed Cell Death 1 ReceptorMajor topic
Proto-Oncogene Proteins p21(ras)Major topic
Tumor Suppressor Protein p53Major topic
Adenocarcinoma of Lung
Biomarkers, Tumor
Female
Humans
Male
Mutation
Prognosis
Proteomics

Source PubMed

Download CSV of topics

Cited by683

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 852 citations.

PMIDTitleJournalYearIn PapersSource
42938349Clinical Utility of Broad-Panel Profiling in Non-Small Cell Lung Cancer: Pairwise Co-Mutational Gene Patterns and PD-L1 Associations Define Stage-Specific Prognosis.Genes (Basel)2026https://conductscience.org/library/papers/42938349PubMed
42936912Uncovering KRAS-mutant allele-specific biology and vulnerabilities in non-small cell lung cancer.Biochem J2026https://conductscience.org/library/papers/42936912PubMed
42934724The evolving role of TP53 mutation in hepatocellular carcinoma (HCC).Cancer Cell Int2026https://conductscience.org/library/papers/42934724PubMed
42870812Impact of different TP53 mutation subtypes on response and outcome in advanced lung adenocarcinoma receiving first-line immunotherapy or chemo-immunotherapy.Transl Lung Cancer Res2026https://conductscience.org/library/papers/42870812PubMed
42852084The lung-gut-brain axis in non-small-cell lung cancer: a narrative review with a systematic search of three signaling pathways.Front Immunol2026https://conductscience.org/library/papers/42852084PubMed
42762412SERPINE1 promotes CRC cell invasion and metastasis through resistance to anoikis.Mol Cell Biochem2026https://conductscience.org/library/papers/42762412PubMed
42761382Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC.Genes Dis2027https://conductscience.org/library/papers/42761382PubMed
42738389Real-World Treatment Patterns and Clinical Outcomes After First-Line Therapy in Patients with KRAS G12C-Mutant Advanced Non-Small-Cell Lung Cancer in the United States.Cancers (Basel)2026https://conductscience.org/library/papers/42738389PubMed
42733756Prevalence of High Programmed Death-Ligand 1 Expression in Pulmonary Sarcomatoid Carcinoma: A Systematic Review and Meta-Analysis.JTO Clin Res Rep2026https://conductscience.org/library/papers/42733756PubMed
42726875Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1.Sci Adv2026https://conductscience.org/library/papers/42726875PubMed
42724286A narrative review of immune checkpoint inhibitor-related cardiotoxicity in lung cancer: mechanisms, risk stratification, and clinical management.J Thorac Dis2026https://conductscience.org/library/papers/42724286PubMed
42629524Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.Apoptosis2026https://conductscience.org/library/papers/42629524PubMed
42500683KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis.Front Immunol2026https://conductscience.org/library/papers/42500683PubMed
42452696KRAS Mutation Subtypes, Co-Mutations, PD-L1 Expression, and Survival Outcomes in Non-Small Cell Lung Cancer.J Clin Med2026https://conductscience.org/library/papers/42452696PubMed
42431967Genetic drivers of etiologic heterogeneity in thyroid cancer.Nat Commun2026https://conductscience.org/library/papers/42431967PubMed
42414255Aging and cancer: current understandings and future perspectives.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42414255PubMed
42409767mTORC1 suppression by Trp53 mutation drives resistance to immune checkpoint blockade.Cell Death Dis2026https://conductscience.org/library/papers/42409767PubMed
42327096mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment.bioRxiv2026https://conductscience.org/library/papers/42327096PubMed
42304441Immunotherapy resistance in colorectal cancer: therapeutic strategies and biomarker-guided approaches.Cancer Cell Int2026https://conductscience.org/library/papers/42304441PubMed
42297823Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer.Nat Commun2026https://conductscience.org/library/papers/42297823PubMed

See all 683 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
IFNG3458PubTator's text mininghttps://conductscience.org/library/genes/3458NCBI Gene
KRAS3845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
TP537157PubTator's text mininghttps://conductscience.org/library/genes/7157NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28039262

GET https://conductscience.org/api/papers/v1/28039262/cited_by?page=2